Adequacy of endoscopic recognition and surveillance of gastric intestinal metaplasia and atrophic gastritis: A multicentre retrospective study in low incidence countries.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
02
2023
accepted:
08
06
2023
medline:
26
6
2023
pubmed:
23
6
2023
entrez:
23
6
2023
Statut:
epublish
Résumé
Gastric atrophy (GA) and gastric intestinal metaplasia (GIM) are precursor conditions to gastric adenocarcinoma (GAC) and should be monitored endoscopically in selected individuals. However, little is known about adherence to recommendations in clinical practice in low-risk countries. The aim of this study was to evaluate endoscopic recognition and adequacy of surveillance for GA and GIM in countries with low GAC prevalence. We retrospectively analysed patients diagnosed with GIM or GA in three centers in The Netherlands and UK between 2012 and 2019. Cases with GIM and/or GA diagnosis at index endoscopy were retrieved through systematic search of pathology databases using 'gastric' and 'intestinal metaplasia' or 'atrophy' keywords. Endoscopy reports were analysed to ascertain accuracy of endoscopic diagnoses. Adequacy of surveillance was assessed following histological diagnosis at the index endoscopy based on ESGE guidelines published in 2012. We included 396 patients with a median follow-up of 57.2 months. Mean age was 66 years and the rates of antrum-predominant versus extensive GIM were comparable (37% vs 38%). Endoscopic recognition rates were 48.5% for GA and 16.3% for GIM. Surveillance was adequately carried out in 215 of 396 patients (54.3%). In countries with a low incidence of GAC, the rate of endoscopic recognition of gastric pre-cancerous lesions and adherence to surveillance recommendation are low. Substantial improvement is required in endoscopic training and awareness of guidelines recommendation in order to optimise detection and management of pre-malignant gastric conditions.
Sections du résumé
BACKGROUND
Gastric atrophy (GA) and gastric intestinal metaplasia (GIM) are precursor conditions to gastric adenocarcinoma (GAC) and should be monitored endoscopically in selected individuals. However, little is known about adherence to recommendations in clinical practice in low-risk countries.
OBJECTIVE
The aim of this study was to evaluate endoscopic recognition and adequacy of surveillance for GA and GIM in countries with low GAC prevalence.
METHODS
We retrospectively analysed patients diagnosed with GIM or GA in three centers in The Netherlands and UK between 2012 and 2019. Cases with GIM and/or GA diagnosis at index endoscopy were retrieved through systematic search of pathology databases using 'gastric' and 'intestinal metaplasia' or 'atrophy' keywords. Endoscopy reports were analysed to ascertain accuracy of endoscopic diagnoses. Adequacy of surveillance was assessed following histological diagnosis at the index endoscopy based on ESGE guidelines published in 2012.
RESULTS
We included 396 patients with a median follow-up of 57.2 months. Mean age was 66 years and the rates of antrum-predominant versus extensive GIM were comparable (37% vs 38%). Endoscopic recognition rates were 48.5% for GA and 16.3% for GIM. Surveillance was adequately carried out in 215 of 396 patients (54.3%).
CONCLUSION
In countries with a low incidence of GAC, the rate of endoscopic recognition of gastric pre-cancerous lesions and adherence to surveillance recommendation are low. Substantial improvement is required in endoscopic training and awareness of guidelines recommendation in order to optimise detection and management of pre-malignant gastric conditions.
Identifiants
pubmed: 37352223
doi: 10.1371/journal.pone.0287587
pii: PONE-D-23-03805
pmc: PMC10289343
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0287587Informations de copyright
Copyright: © 2023 Honing et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Dig Dis Sci. 2023 Mar;68(3):761-769
pubmed: 35689702
Dig Dis Sci. 2010 May;55(5):1364-75
pubmed: 19629687
Gastroenterology. 2021 Oct;161(4):1325-1332.e7
pubmed: 34454714
Cell Oncol. 2007;29(1):19-24
pubmed: 17429138
Pol Arch Intern Med. 2022 Apr 28;132(4):
pubmed: 35089676
Endoscopy. 2022 Jul;54(7):653-660
pubmed: 34674210
Dig Dis. 2020;38(4):286-292
pubmed: 31655807
Endoscopy. 2019 Jun;51(6):515-521
pubmed: 30577062
Gastrointest Endosc. 2022 Feb;95(2):239-245.e2
pubmed: 34499903
Lancet. 2020 Aug 29;396(10251):635-648
pubmed: 32861308
Therap Adv Gastroenterol. 2022 Sep 3;15:17562848221117640
pubmed: 36082176
Am J Gastroenterol. 2015 Apr;110(4):489-96
pubmed: 25267326
Medicina (Kaunas). 2007;43(8):623-9
pubmed: 17895638
Gut. 2019 Sep;68(9):1545-1575
pubmed: 31278206
Gastrointest Endosc. 2017 Nov;86(5):857-865
pubmed: 28366441
Eur J Gastroenterol Hepatol. 2014 Jun;26(6):594-601
pubmed: 24743505
Endoscopy. 2022 Jul;54(7):644-652
pubmed: 34666399
Dig Dis Sci. 2010 Dec;55(12):3442-8
pubmed: 20393882
Gastrointest Endosc. 2022 Sep;96(3):467-475.e1
pubmed: 35413331
PLoS One. 2022 Dec 30;17(12):e0275232
pubmed: 36584163
Gastrointest Endosc. 2021 Sep;94(3):540-548.e4
pubmed: 33722576
Dig Dis Sci. 2016 Sep;61(9):2674-84
pubmed: 27129486
Am J Gastroenterol. 2010 Mar;105(3):493-8
pubmed: 20203636
Gastroenterology. 2022 Apr;162(4):1123-1135
pubmed: 34958760
Clin Gastroenterol Hepatol. 2019 Feb;17(3):429-439
pubmed: 29902641
J Clin Gastroenterol. 2022 Nov 21;:
pubmed: 36413030
Gut. 2022 May;71(5):854-863
pubmed: 33975867
Endoscopy. 2012 Jan;44(1):74-94
pubmed: 22198778